An interventional study of hysteroscopy and Aspiration in Miscarriage, sponsored by University Hospital, Montpellier. Recruiting at 4 sites in France. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Abortion, Spontaneous with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Abortion, Spontaneous · France.
Among the 27 studies in Abortion, Spontaneous with a site in France, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 12 with no phase, and was the 21st registered.
221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.
Browse Abortion, Spontaneous studies →7 of the 27 studies in Abortion, Spontaneous with a site in France are open now. Recruiting first, the newest first:
Rennes University Hospital · Sites in France
Ages 18–43 · Women only
University Hospital, Toulouse · Sites in France
Ages up to 18 · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–50 · Women only
University Hospital, Brest · Sites in France
Ages 18–40
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 220 is above the median of 150 across 120 interventional studies indexed under Abortion, Spontaneous.
Median enrollment 210 across the 14 interventional studies, 202 across the 13 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
University Hospital, Montpellier has 4 studies filed under Abortion, Spontaneous — fewer than ten, so there is no comparison to draw.
5 of the studies in Abortion, Spontaneous with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06576622University Hospital, ToulousePERIodontal Disease, Microbiota and Miscarriage | 2026-12-30 |
| NCT07732231Nantes University HospitalCost-utility Analysis of Outpatient Manual Vacuum Aspiration Versus Operating Room Electric Aspiration for the Management of First-trimester Miscarriage | 2027-01-01 |
| NCT06647849University Hospital, AngersInterest of Simulation Training on the Announcement of Early Pregnancy Loss on the Psychological Impact of the Patients | 2027-06-11 |
| NCT05789940University Hospital, MontpellierHysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention | 2027-09-18 |
| NCT05557201Assistance Publique - Hôpitaux de ParisCohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Abortion, Spontaneous with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.
Aim: The main objective is to compare the efficacy of management by endo-uterine aspiration vs. management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.
Methods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.
Patients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:
Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.
Aim: The main objective is to compare the efficacy of management by endo-uterine aspiration versus management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.
The secondary objectives are:
Methods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.
Patients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:
Statistics: The effectiveness of operative hysteroscopy is expected to be 100%, and that of aspiration 90%. To show this difference with an alpha risk of 5%, and with a power of 90%, 98 patients per arm will have to be analysed (exact binomial distribution calculation, epiR package of R implemented in biostatgv). To take into account a 10% loss of sight rate, 220 patients will be recruted.
Patients will be included in the study on the morning of the procedure, after verification of the selection criteria.
The expected number of lost to follow-up is estimated at 10%; in fact, the main criterion is evaluated relatively early (6 weeks), in patients having a desire for pregnancy and therefore relatively compliant, the rate of lost to follow-up will be a fairly low.
A flow-chart will be constructed to describe the evolution of the populations during the study. It will detail the causes of non-inclusion and the causes of loss to follow-up.
All study data will be described according to the randomization arm, in the randomized population: mean, standard deviation, median and quartiles, extrema and number of missing data for quantitative variables, numbers and percentages of each modality for qualitative data.
The clinical comparability of the randomized population and the ITT population for the primary endpoint will be assessed.
Primary analysis:
The uterine vacuity rate will be compared between the two arms in the ITT population for the primary endpoint by a Chi-square test or by a Fisher exact test if the conditions for Chi-square validity are not met. The significance level was set at 5%, two-sided.
Secondary endpoint analysis:
The rates of complications, use of second-line surgical management, synechiae, and fertility at 2 years after surgery will be compared between the two arms in their respective ITT populations, by a Chi-square test or by a Fisher's exact test if the conditions for the validity of Chi-square are not met.
The time to conception will be compared between the two arms of the randomized population by a log-rank test.
Within this family of endpoints, the alpha risk will be controlled by a Hochberg procedure.
Visit 1: Pre-operative consultation between 1 and 21 days before the operation
At the end of the consultation:
Intervention (D0):
Visit 2: Consultation at 6 weeks after surgery +/- 7 days
This consultation will be performed by an investigator trained in pelvic ultrasound and hysterosonography, blinded to the allocated procedure:
Visit 3: Telephone consultation at 6 months +/- 15 days after surgery
Carried out by the clinical research associate (CRA):
Visit 4: Telephone consultation at 12 months +/- 1 month after surgery
Carried out by the CRA:
Visit 5: Telephone consultation at 24 months (+/- 2 months) after surgery
Carried out by the CRA:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients randomized to the hysteroscopy arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery, and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.
Procedure: hysteroscopy
Patients randomized to the aspiration arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.
Procedure: Aspiration
The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
Uterine vacuity
Uterine vacuity will be determined by endovaginal pelvic ultrasound. The endovaginal pelvic ultrasound will be performed by an investigator blinded to the patient's group, in order to minimize bias. It will be performed according to a standard pelvic ultrasound technique: a sagittal section and a transverse section passing through the widest part of the uterine body. Uterine vacuity will be defined by a thickness of the mucosa on a sagittal section of 15 mm or less and the absence of a heterogeneous intrauterine mass
Time frame: 6 weeks after surgery
Difference between the two arms in complication rates
Complications will be described according to clavien-dindo classification
Time frame: During surgery and 6 weeks after surgery
Difference between the two arms in the rate of second line surgical management
The rate of second line surgical management will be described
Time frame: During surgery
Difference between the two arms in synechia rates
Presence of synechia will be assessed by hysterosonography
Time frame: 6 weeks after surgery
Difference between the two arms in mean time to conception
Patients will be contacted by phone at 6, 12 and 24 months after the surgery to ask if they have been pregnant et evaluate the time of conception
Time frame: 6, 12 and 24 months after surgery
Difference between the two arms in pregnancy rates
Patients will be contacted by phone at 6, 12 and 24 months after the surgery to assess their fertility
Time frame: 6, 12 and 24 months after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.
Of 43 non-industry interventional studies with no phase under Abortion, Spontaneous, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 48 months is above that.
Counting every sponsor, half of 45 studies reached it within 27 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →